Merck hits the brakes on development program as safety fears trigger alarm

In a surprise setback, Merck has slammed the brakes on the development of an experimental HIV drug — including a Phase II trial — after investigators flagged a drop in immune cell counts that an external committee determined was related to treatment.

The Phase II study that first

Click to view original post